Cargando…
Genetic polymorphisms of SCN9A are associated with oxaliplatin-induced neuropathy
BACKGROUND: Oxaliplatin is a chemotherapy agent active against digestive tumors. Peripheral neuropathy is one of the most important dose-limiting toxicity of this drug. It occurs in around 60–80% of the patients, and 15% of them develop severe neuropathy. The pathophysiology of oxaliplatin neurotoxi...
Autores principales: | Sereno, María, Gutiérrez-Gutiérrez, Gerardo, Rubio, Juan Moreno, Apellániz-Ruiz, María, Sánchez-Barroso, Lara, Casado, Enrique, Falagan, Sandra, López-Gómez, Miriam, Merino, María, Gómez-Raposo, César, Rodriguez-Salas, Nuria, Tébar, Francisco Zambrana, Rodríguez-Antona, Cristina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5248487/ https://www.ncbi.nlm.nih.gov/pubmed/28103821 http://dx.doi.org/10.1186/s12885-016-3031-5 |
Ejemplares similares
-
Lung cancer and peritoneal carcinomatosis
por: SERENO, MARÍA, et al.
Publicado: (2013) -
Severe emphysematous cystitis:
Outcome after seven days of
antibiotics
por: Sereno, Maria, et al.
Publicado: (2011) -
A favorable outcome of pneumonia COVID 19 in an advanced lung cancer patient with severe neutropenia: Is immunosuppression a risk factor for SARS-COV2 infection?
por: Sereno, María, et al.
Publicado: (2020) -
1752P Epidemiological analysis of SARS-CoV-2 virus infection in patients with solid tumors: The experience of Infanta Sofía University Hospital (HUIS)
por: Gomez Raposo, C., et al.
Publicado: (2020) -
Management of oxaliplatin-induced peripheral neuropathy
por: Saif, M Wasif, et al.
Publicado: (2005)